BACKGROUND: Alloimmunization through blood transfusion, transplantation, or circulating fetal cells during pregnancy is a significant concern. Some exposed individuals make alloantibodies while others do not, implying variation in genetic risk factors.
, for women with anti-Class I alloantibodies only. Little is currently known about the function of NXPH2, although gene family members have been shown to impact immunity. SNPs in the E2F7 gene, a transcription factor related to cell cycle control and cellular proliferation, also approached genomewide significance (p 5 2.5 3 10 27 ).
CONCLUSION:
Further work to extend the GWAS approach and to characterize variants in NXPH2 and E2F7 in the context of alloantibody formation is warranted. I t has been appreciated for more than 50 years that pregnancy can lead to alloimmunization, 1 and hightiter HLA antibodies can persist for decades after pregnancy. 2 Successive pregnancies carry further risk for antibody formation. Using sensitive assays for detection of HLA antibodies, it was shown that approximately 10% of women are alloimmunized after one pregnancy, and this increases to approximately 30% of women after four or more pregnancies. 3 Alloimmunization is also a significant clinical problem in transfusion medicine. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] While this is usually not problematic for recipients who experience limited exposures to allogeneic blood products, alloimmunization is a concern for those who depend on regular platelet (PLT) or red blood cell (RBC) transfusions, including patients with hematologic malignancies or myelodysplastic disease or patients with sickle cell disease and other inherited hemoglobin disorders (RBC dependent). Currently, leukoreduction of transfusion products, 3, 5, 16 prophylactic transfusion of antigenmatched RBC units, 5, 18, 19 and frequent laboratory monitoring for new antibody formation with subsequent use of cross-match-compatible blood components 5, 9, 18 are the only tools available to manage transfusion therapy in patients with antibodies to RBC, HLA, or PLT antigens. Both prior pregnancy and blood transfusion were identified as major contributors to HLA alloimmunization for subjects awaiting kidney transplant. 20 The presence of HLA antibodies is associated with increased risk for rejection and graft failure, both acutely 21 and over the lifetime of the graft.
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Alloimmunization-whether to RBC, PLT-specific, or HLA antigens, depending on the type of blood product received or other exposure-occurs in roughly onethird of blood recipients in the absence of full or partial RBC antigen matching or leukoreduction. [5] [6] [7] 14, 19, 23 This consistency in the alloimmunization rates among individuals, regardless of the type of exposure (e.g., RBC, HLA, or PLT antigen antibodies after transfusions or even HLA alloimmunization after pregnancy), together with indications of overlap among the subpopulations vulnerable to alloimmunization across these various exposures, suggests the existence of host susceptibility factors that are likely to be in part genetically determined. 6, 8, 12, 24 Similar conclusions were reached with a mathematical model based on a database of thousands of transfusion recipients in diverse patient populations. 23, 25, 26 Data from the transplantation setting suggest that women who are not alloimmunized during pregnancy are less likely to develop donor-specific antibodies after transplantation. 27 Recent technologic developments (i.e., highthroughput, genomewide single-nucleotide polymorphism [SNP] genotyping using commercial arrays) enable the comprehensive search for genetic variation associated with differing risks of alloimmunization. 28 Here we report the results of a genomewide association study (GWAS) including 752 alloantibody-positive and 753 alloantibody-negative, previously pregnant female blood donors who had been enrolled in the Leukocyte Antibody Prevalence Study (LAPS). We found associations exceeding genomewide significance for SNPs within the NXPH2 gene and close to genomewide significance for the E2F7 gene.
MATERIALS AND METHODS

Study subjects
Subjects were drawn from the previously conducted Retrovirus Epidemiology Donor Study-II (REDS-II) LAPS  cohort, 3,17 a multicenter cross-sectional study designed to measure the prevalence and laboratory characteristics of HLA and neutrophil antibodies in blood donors with and without a history of known allogeneic exposures through blood transfusion or pregnancy. The LAPS protocol involved a questionnaire for enrolled donors that characterized donors for transfusion and pregnancy history, in addition to routine demographic variables such as age, race-ethnicity, and sex. Donors gave specific consent to studies of genetic factors that may be involved in immune reactions to pregnancy and transfusion, including alloimmunization. Each subject in the LAPS repository has been tested for Class I and II HLA alloantibodies and classified as positive if the signal on the detection assay was three standard deviations (SDs) above the mean found in 1138 nontransfused males. 3 All subjects included in the present analysis were female and reported a history of pregnancy.
Given that blood donors are enriched for subjects reporting white or European ancestry and the fact that population stratification decreases power due to differential linkage disequilibrium across ethnic groups, 29 the analysis was limited to subjects reporting white or European ancestry. All 772 eligible subjects with detectable HLA alloantibodies were included as cases, and they were matched with an equal number of subjects without detectable HLA alloantibodies as controls. To maximize potential alloexposure in the nonimmunized control population, women with the greatest number of reported pregnancies were selected (two or more prior pregnancies for all subjects). A second set of samples from 373 transfused subjects from the Trial to Reduce Alloimmunization to Platelets (TRAP) 30 was examined to determine if the lead SNP implicated in the LAPS GWAS would associate with alloimmunization risk after transfusion. These samples were obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioL-INCC). Our group had previously tested these subjects for HLA antibody status before and serially after transfusion.
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Sample genotyping and data quality control
Two of the selected samples lacked sufficient DNA, and the remaining 1542 subjects were genotyped with the Illumina Omni 1 array, containing probes for 1,008,624 SNPs. Subjects with less than 99% call rate were eliminated (n 5 15), as well as planned and unexpected sample duplicates (identity by state > 90%; n 5 11); cryptic first-degree relatives (identity by descent > 10%; n 5 11, six parentoffspring and five full siblings); and nonfemale sex on the basis of X-chromosome zygosity (n 5 0). A total of 752 alloantibody-positive and 753 alloantibody-negative subjects passed these quality control (QC) thresholds and were included in subsequent analyses. SNPs with a call rate of less than 99% (n 5 76,122) and Hardy-Weinberg disequilibrium in controls with p < 0.00001 (n 5 288) were discarded, leaving 932,214 SNPs for analysis. Genotype imputation was performed using IMPUTE2 and the Phase I integrated variant set release (v3) 32, 33 and the 1000 Genomes cosmopolitan reference haplotypes.
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This resulted in genotype calls for a total of 38,066,487 SNPs and insertion/deletion polymorphisms (indels), but only the 9,427,497 variants with a minor allele frequency of more than 0.01 with and Rsq > 0.85 in the 1000 Genomes European super population were analyzed further. In addition, imputation of four-digit HLA alleles was performed with HLA*IMP:02. 35 Postimputation QC followed the same criteria that were applied to the genotyped SNPs. No SNPs were eliminated on the basis of Rsquared; rather, R-squared and dosage were used to adjust the associations.
Genotype analyses
After imputing a common set of SNPs and combining cases and controls into a single data set, EIGENSTRAT 36 was used to compute principal components based on the genotyped markers. No subjects were found to decrease more than 2 SDs from the median of the centroid of the self-reported Caucasian samples in the first three dimensions of eigenvalue space, and thus no population outliers were excluded. An initial screen to test for association across the major histocompatibility complex and then the entire genome was performed by examining allele and genotype frequency distributions in the data set of alloantibody positive and negative individuals. We generated allele frequencies for each SNP and performed association tests for allele counts in cases and controls using a Cochran-Armitage trend test (1 degree of freedom per SNP).
Determining HLA discordance between mother and child
Alloantibody formation is more likely if the HLA alleles of the mother and those of her fetus differ. While the tremendous allelic diversity of the HLA loci makes it unlikely that a mother and fetus will be HLA identical, we addressed this possibility in a substudy including approximately 250 mothers from LAPS. For these subjects, the father and at least one child were also enrolled and directly typed for DRB1 alleles, with SNP-based imputation available for the remaining Class I and Class II loci. This enabled us to determine the extent of HLA matching between motherchild pairs and to correlate that with the risk of alloimmunization in the approximately one-third of mothers exhibiting HLA alloantibodies.
RESULTS
Genomewide association with alloimmunization
Principal components analysis of cases and controls was consistent with the self-reported European ancestry of all study subjects (Fig. S1 , available as supporting information in the online version of this paper). There was no evidence of inflated p values from population stratification across the four main association analyses, after adjustment for the first two principal components. Statistics of association among cases (those with alloantibodies) and controls were calculated for each of four different alloantibody scenarios and plotted as negative log p values by chromosome ( Fig. 1 Fig. 2A , which illustrates that the SNPs exhibiting association are coincident with the entire span of the NXPH2 gene. Recombination hotspots at both ends of the NXPH2 gene define the precise limits of the associated SNPs, which strongly implicates variants in this gene alone as responsible for the signal of association. The second most significant locus for Class I alloantibodies is on chr12, just 5 0 of the E2F7 gene (Fig. 2B ), although these SNPs do not exceed genomewide significance (rs7487338; p 5 2.4 3 10
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; OR 5 0.41 [0.29-0.57]), and this result will require additional replication. None of the other analyses of alloantibodies against Class I, Class II, or both Class I and Class II antigens resulted in association statistics that reached genomewide thresholds of significance.
Examination of NXPH2 in a cohort of transfusion recipients
As part of LAPS, information on prior transfusion but not transplantation was collected. We examined if the rate of prior transfusion differed between women who did or did not form HLA Class I antibodies and found no difference in the rate of transfusion between those with or without HLA Class I antibodies (8.8% vs. 9.5%, p 5 0.8). To determine if the association between the NXPH2 minor allele variant and alloimmunization was limited to exposure via pregnancy, we genotyped a cohort of 373 wellcharacterized samples from subjects in the TRAP trial for whom samples were available for genotyping and determination of HLA alloimmunization. TRAP participants were subjects with acute myelogenous leukemia who received transfusion and did or did not get alloimmunized. 30 Using the lead implicated SNP rs62163199, we were able to determine that nine subjects were homozygous for the AA allele, 99 were heterogeneous, and 265 were homogeneous for the GG allele (Tables 1 and 2 ). The proportion of alloimmunized AA homozygous subjects was not significantly different compared to the proportion of alloimmunized AG and GG subjects (p 5 0.4).
HLA associations with alloimmunization
Given the centrality of HLA variation itself in the production of antibodies, and the prominent association signals in the HLA region for autoimmune diseases that are characterized by the presence of particular autoantibodies (e.g., rheumatoid arthritis and systemic lupus erythematosus), we might have expected to see association at the HLA region on chr6. This hypothesis, and the failure to observe a simple association for SNPs spanning the HLA region, prompted us to examine in more detail the HLA region using fully imputed HLA alleles for HLA-A, -B, -C, -DP, -DQ, and -DR. We first compared imputed alleles at HLA-DRB1 with those determined directly by conventional DNA sequencing methods. Concordance at the two-digit level, which corresponds roughly with the serologic reactivities of the HLA alleles, reached 98% and dropped to only 87% at the four-digit level. This result provided sufficient confidence to examine more detailed associations with particular HLA alleles among cases and controls (Tables 3-6 , which examine homozygous alleles only). Looked at in this way, particular allelic pairings do appear to be associated, despite the much smaller counts for specific alleles. None surpass genomewide significance, but do surpass thresholds of significance for a six-locus test of just the HLA region itself. The most significant association is for HLA-B7 homozygosity, which is greatly overrepresented in cases versus controls.
Effect of mother/child HLA disparity on alloimmunization rate
Finally, for a subset of mothers in this study, we had imputed (or, for DRB1, directly typed) HLA allele data for one or more of her children and her husband. This enabled us to look for the frequency with which mothers may have been exposed to mismatching alloantigens (from the father) via the fetus during pregnancy. One of the most obvious reasons for a failure to produce alloantibodies during pregnancy is if both parents are matched at most or all HLA loci. Given the sheer diversity of HLA variation in this population, it would be rare statistically for spouses to share many HLA alleles, and there are compelling data to indicate that some degree of disassortative mating occurs in humans for HLA variants, such that spouses are mismatched even beyond what is expected on the basis of allele frequencies in the population. 37 The degree of HLA discordance between mother and spouse did not differ between women who were or were not alloimmunized (Table 7) . However, women who developed HLA Class I antibodies showed a trend to a higher degree of HLA mismatch with their children than nonalloimmunized women, and for development of HLA Class II antibodies, those who were alloimmunized were significantly more mismatched with their progeny (Fig. 3 , Table  8 ). Based on Table 7 , even in pregnancies that do not result in alloantibody formation in the mother, the fetus presents nonself HLA antigens that have the potential to result in alloantibody production in the mother.
DISCUSSION
Our primary finding shows an association between SNPs in and near the NXPH2 gene and the presence of HLA Class I alloantibodies in a population of previously pregnant women. Members of this gene family were first described in the context of neural signaling, but are expressed widely and probably have functions well beyond the neural system. 38 Neurexophilins are secreted and have been described as detectable in plasma, and a member of the same family, NXPH1, has been shown to influence growth of hematopoietic progenitor cells. 39 In a preliminary GWAS using sliding windows, a SNP within NXPH2 has been associated with rheumatoid arthritis. 40 SNPs in NXPH2 have also been associated with male infertility and alcohol dependency. 41, 42 Given the large effect size of variation in the NXPH2 gene on the risk for alloimmunization and its known role in cell signaling in the neural system, it is plausible that this protein would have an effect on the immune system and the propensity to develop alloantibodies. A parallel example is found in neuropilin-1, which is important for axon guidance but also has been identified as an important marker of regulatory T cells. 43 Neurexophilins are known to bind to neurexins and other ligands, and NXPH1 has been shown to bind to and influence the growth of hematopoietic progenitor cells. 39 Whether or not NXPH2 can interact with cells of the immune system has not yet been studied, but our genetic association data and the prior literature suggests that such an interaction is possible. The implicated SNPs within NXPH2 are contained in the midst of a single, long intron. How the SNPs are related to the effect on alloimmunization is potentially via modulation of expression of NXPH2 or other mechanisms dependent on intragenic sequence such as long, noncoding RNA (lncRNA) modulation of neighboring genes. While the minor allele variant of NXPH2 appeared to confer a modest to strong increased risk for the development of HLA Class I antibodies in pregnancy (OR, 1.96), there was no association between NXPH2 SNPs and the risk of becoming sensitized to HLA Class II antibodies. If this finding were to be confirmed, it would help design further studies about the pathway of allosensitization during pregnancy and for the identification of candidate genes that are necessary for the responder status. From epidemiologic studies of pregnant women it is known that of those who become alloimmunized, nearly equal proportions will develop antibodies against HLA Class I antigens only, Class II antigens only, or both Class I and II antigens, with the last category slightly less common than the first two. 18 Why women develop Class I versus Class II allosensitization is not clear, although it is known that there is differential regulation of expression of these antigens on fetal cells. The fetal cell with the most direct exposure to the maternal immune system is the trophoblast. In these cells HLA Class II expression is suppressed due to lack of Class II transactivator (CIITA) expression 45, 46 that is mediated via methylation of the CIITA interferon-cresponsive promoter (PIV). 47 Trophoblasts also lack expression of most HLA Class I molecules, with exception of the nonclassical molecules HLA-C, 48 HLA-E, 49 and HLA-G. 50 It is possible that NXPH2 could interact differentially with the epigenetic pathways that silence HLA Class I versus Class II molecules in trophoblasts. In addition to direct exposure to trophoblasts, fetal DNA and cells can be detected in maternal circulation during gestation. 51 Finally, a major potential source of fetal interaction with maternal blood is during parturition. For these last two routes of exposure, most of the cells that would be seen by the maternal immune system would express HLA Class I but not Class II, with the exception of professional antigen-presenting cells. There are several differences between HLA Class I and II antigen presentation in pregnancy and in nonpregnant subjects, and it is not clear which mechanism would underlie a differential ability of NXPH2 to protect from HLA Class I but not Class II alloimmunization. A second cluster of SNPs that approached but did not achieve genomewide significance was 5 0 of the E2F7 gene.
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E2F transcription factors comprise a family that is important in regulation of cell cycle, apoptosis, and cellular differentiation. 52 Expression of E2F7 is cell cycle regulated, the protein binds DNA and localizes to the nucleus, and it blocks E2F-dependent activation. 53, 54 The net result of E2F7 suppression of cellular proliferation is cells accumulating in G1 phase of cellular division. 54 E2F7 has not been previously reported to be associated with alloimmunization risk or immune function and presumably if it did affect alloimmunity it would be through its influence on cellular proliferation.
Interestingly, in the initial GWAS analysis we did not find genomewide association for alloresponse to HLA region genes. But on more detailed analysis of imputed alleles for HLA-A, -B, -C, -DR, -DQ located in the HLA region, we found that HLA-B7 homozygosity was overrepresented in responders compared to the nonresponders. Similar to our findings, overrepresentation of HLA-B35 in sickle cell anemia patients with RBC alloimmunization has been shown by others. 55 We were able to detect antigen disparity between the mother and the child by performing HLA typing of mother-child-father combinations in a subset of the study subjects. As has been demonstrated previously, we found a greater degree of antigen disparity between the mother and the child than would be expected by the known antigen frequencies in the population. 56 This indicates that most pregnancies result in alloexposures, supporting a role for genetic variation and other factors in the susceptibility to becoming alloimmunized. It has been described in the transplant literature that certain HLA mismatch pairs are more likely to result in generation of alloantibodies. 57 It was beyond the scope of this study to perform detailed analysis of maternal-fetal HLA mismatches, but such an analysis could complement the extensive data available in the transplant field. 58 There were several limitations of the study that bear mentioning. This study was limited to women who identified as white or European ancestry, so further study would be needed to demonstrate whether or not the identified genetic variations also influenced alloimmunization across other ethnic groups. The assay cutoff used to determine allosensitization was 3 SDs above the mean found in nontransfused males, so associations between novel genetic polymorphisms and generation of low-level antibodies in previously pregnant females could have been missed. Imputation of HLA alleles was performed, which has a high degree of accuracy, but a small percentage of imputed alleles may have been incorrect.
The findings reported here should motivate larger genetic studies in search of variants associated with HLA alloimmunization, as well as RBC-and PLT-derived alloimmunization in other transfusion medicine contexts, although our modestly sized study of 373 individuals from the TRAP study did not reveal an association between NXPH2 and alloimmunization due to PLT transfusion. This will enable a better understanding of the functional basis for alloimmunization, as well as identifying the degree to which genetic associations are shared or different according to the type of alloexposure. In addition, this study was conducted using only subjects reporting European ancestry, so replication studies would ideally be performed using an ethnically diverse population. Finally, functional studies to elucidate the role of NXPH2 in the alloimmunization process should be a priority and could suggest novel therapeutic targets for the modulation of alloimmunization risk during pregnancy and other alloex Fig. S1 . Principal components analysis (PCA) including study samples with 1000 Genomes samples for the first three PCAs. RED 5 Samples in this study, ORANGE 5 African Americans, BLUE 5 European, YELLOW 5 Chinese, GREEN 5 Mexican, BLACK 5 African.
